ZS Pharma Inc (NASDAQ:ZSPH) - Share price - Overview

Stock Report

ZS Pharma Inc ZSPH

Last Price
$-

Day Change
-|-%

As of -
- | USD
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap2.27Bil
52-Wk Range-
Yield %-
ISINUS98979G1058
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201220132014
More ...
Income Statement
Revenue0.000.000.00
Operating Income-8.14-32.19-60.54
Net Income-10.28-33.60-64.04
Basic EPS--3.17-5.47
Avg. Diluted Shares Outstanding-1012
Balance Sheet
Current Assets24.419.40103.26
Non Current Assets1.204.6512.91
Total Assets25.6214.05116.16
Current Liabilities1.604.689.14
Total Liabilities38.7659.2319.39
Total Equity-13.15-45.1896.77
Cash Flow
Operating Cash Flow-7.17-26.53-49.02
Capital Expenditure-0.71-3.77-8.00
Free Cash Flow-7.88-30.30-57.02

In millions, except "Basic EPS". Currency is USD.

Company Profile

ZS Pharma Inc is a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

Sector

Healthcare

Industry

Drug Manufacturers - Major

Fiscal Year Ends

December

Employees

184
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % TTM-Infinity
Net Margin % TTM-Infinity
ROE TTM-255.40
Debt/Equity0.10
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.